|ORGANISED AND VIDEO IS AVAILABLE|
➡️ Recorded: Wednesday 17 June 2020
➡️ Language: English
➡️ Duration: 30 min
▷ Presenter: Prof. FLORIAN LAGLER, Paracelsus Medical University in Salzburg, Austria
Learning Objectives: (1) Limitations of current therapies (2) State of development of emerging therapies (3) Active mechanisms of emerging therapies (4) Limitations of emerging therapies
- Florian B Lagler is a Pediatrician and board-certified Pharmacologist and Toxicologist. He is a Clinical/Translational Researcher in the field of lysosomal storage diseases (LSDs) and other inborn errors of metabolism. Dr Lagler trained in pediatrics and pediatric metabolic medicine (1999–2004, Dr von Hauner Children’s Hospital, Munich, Germany) and basic and clinical pharmacology (2004– 2011, the Medical University of Innsbruck, Austria). He is Head of the Institute for Hereditary Metabolic Diseases at Paracelsus Medical University in Salzburg, Austria and CEO of the Clinical Research Center Salzburg. In his clinic, he sees patients with Fabry disease, Gaucher disease, Pompe disease, MPS and other lysosomal storage disorders. He serves as an Advisor to the Austrian Agency for Health and Food Safety (AGES), a Drug Commissioner at the German Society of Pediatrics and Adolescent Medicine (DGKJ), an Editor of Monatsschrift Kinderheilkunde, the publication of the German and Austrian Society of Pediatrics and Adolescent Medicine and is the General Secretary of the European Society for Developmental, Pediatric and Perinatal Pharmacology. Dr Lagler also heads up the Salzburg Medical Simulation Center. Together with an international faculty of LSD and emergency medicine experts, he has developed specific simulation training for physicians and nurses who take care of patients with LSDs. This unique training has been provided to more than 500 nurses and physicians from over 25 countries all over the world.
Important Note: The information provided on this session is intended and designed for use by healthcare professionals with an interest in metabolic diseases and MPS. All session viewers are required to register for the selected webinar before accessing the content. Content and views shared are solely those of the speaker.
The course is an MPS Europe project in partnership with MetabERN and the Excellence in Pediatrics with the support of Abeona, Biomarin, Orchard Therapeutics, Regenxbio, Sanofi Genzyme, Takeda, and Ultragenyx. All modules of the course are independently organised by EIP in terms of content, topics and speakers appointed.